Skip to main content

Table 1 Clinical characteristics of systemic lupus erythematosus patients and age- and gender-matched healthy controls

From: Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus

Parameters SLE patients HCs
  (n = 14) (n = 12)
Age (years) 41.0 (26.0–52.0) 43.0 (30.0–51.0)
Gender (% female) 100 100
Disease duration (years) 4.6 (2.2–11.4) -
SLEDAI 4.0 (2.5–6.0) -
SLICC 0.0 (0.0–1.0) -
dsDNA (% ever positive) 79.0 -
dsDNA (IU/mL) 31.5 (10.8–396.8) -
Clinical features (no. of patients)
 Nephritis 0 -
 Arthritis 4 -
 Rash 7 -
 Serositis 2 -
 Leukopenia 6 -
 Oral ulcers 4 -
 Vasculitis 1 -
Treatment (no. of patients)
 None 2 -
 Hydroxychloroquine 6 -
 Azathioprine 4 -
 Cyclophosphamide 1 -
 Mycophenolate mofetil 3 -
 Prednisone 12 -
  1. Values are shown as median (interquartile range) or as number where indicated. dsDNA double-stranded DNA, HC healthy control, SLE systemic lupus erythematosus, SLEDAI SLE Disease Activity Index, SLICC Systemic Lupus International Collaborating Clinics